Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: Numerous bills on expanding access to health care, and growing training and educational opportunities for residents were included among the 134 new measures the Legislative Council accepted last week. The Portland Press Herald reports only the titles of the bill have been submitted for introduction in the lawmaking session that starts in January. The measures also appear to be a response to the recent leaked propane explosion in a building in Farmington. The state has no current regulation requiring natural gas or propane leak detectors or warning devices. Lawmakers will also take up about 500 other measures either held by Gov. Janet Mills or left over from this year's session. Claim: Health care, education to lead Maine's legislative debates.

Answer: Several bills focused on health care and education are expected to lead legislative debates at the Maine Statehouse in 2020.

Question: Paragraph: The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumor types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany's Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial. Traditionally, oncologists have made treatment decisions based on where in the body a tumor started, increasingly helped by the growing knowledge of cancer's complex genetic drivers. Under the tumor-agnostic approach, also known as pan-tumor, drugmakers skip the organ-of-origin perspective and regroup patients based only on signature genetic mutations, but success in real life will depend on the fast spread of comprehensive gene-sequencing tools for tissue samples. Individually, the mutations are so rare that cancer units are seen as unlikely to run dedicated tests for each. Roche's Foundation Medicine supplies the comprehensive kits, competing with Thermo Fisher Scientific and Caris Life Sciences. "It's one of the reasons we acquired Foundation Medicine, to make this comprehensive genomic profiling routine and upfront in the course of the disease," said Daniel O'Day, the head of Roche's Pharmaceuticals division. Loxo's larotrectinib pill, co-developed with Bayer, was last year shown to shrink tumors in 75 percent of patients with the NTRK fusion gene anomaly, occurring in the lung, pancreas, or more than a dozen other organs. On Sunday, the response rate to larotrectinib within an enlarged group of 122 trial participants - up from 55 initially and now spanning 24 tumor types - was shown to be 81 percent. Roche said the readings from the two NTRK fusion trials were not comparable because they are made up of different patient types. Loxo's study, for instance, included some cancers in children, while Roche plans to investigate those separately. The Roche compound is designed to tackle several oncogenic mutations and last month, it unveiled data here on entrectinib pushing back tumors in 77 percent of lung cancer patients with a mutation called ROS1. Merck & Co's Keytruda in May last year became the first drug to win approval for pan-tumor use, though that remains a relatively small market for the mega-selling drug. Bayer and Loxo are testing a second pan-tumor drug, LOXO-195. Roche Pharmaceutical's O'Day welcomed a wider field. "Both things have to happen: You need genomic profiling and you need enough targeted medicines to encourage physicians to make that diagnosis upfront very complete. This is the world we're entering," he said. Though response rates could encourage a race for more such drugs, the need for suitable gene mutations or fusions will be a tall order, said oncologist Ulrik Lassen of Copenhagen's Rigshospitalet, who co-authored the larotrectinib study. "You need to screen a lot of patients to find the needle in the haystack and the method is complicated, costly and time-consuming. When we get better at using these technologies, we can find more oncogenic fusions and companies will be smart enough to find the agents that target them." Roche acquired entrectinib as part of its takeover deal with U.S. cancer drug specialist Ignyta Inc for $1.7 billion, agreed in December last year. Immuno-oncology remains another major business area for Roche, which also released positive results on using its Tecentriq drug in a group of breast cancer patients with a particularly poor prognosis. Claim: Roche takes on Loxo, Bayer in gene-defined cancer class.

Answer: Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

Question: Paragraph: Researchers with the UofA Cooperative Extension are moving forward with a multiyear study of the environment and growing practices in the "winter vegetable capital," the university announced last week. They will be partnering with the U.S. Food and Drug Administration, state agriculture officials and local growers. "It's really rare to see a project like this, to see all three entities working together to solve a problem," Channah Rock, an environmental science professor with the UofA Cooperative Extension, told The Associated Press. Seven to 10 scientists will be based in Yuma and collect data year-round. They will gather samples of water, sediment and wildlife feces, Rock said. The study is expected to last one to three years. One of the goals is to come back with recommendations for growers or anyone along the production chain, and perhaps inform future practices, Rock said. "The goal is to look at trends over time to tell us a better story about what is and isn't going on in the environment," she said. The Centers for Disease Control and Prevention found the spring 2018 outbreak was responsible for five deaths and made 200 others ill. Health officials ultimately traced the romaine lettuce back to Yuma. FDA investigators said water samples from an irrigation canal in eastern Yuma County tested positive for the same genetic type of E. coli. And a cattle feedlot in the area was identified as a potential source of harmful bacteria. However, nothing definitive turned up at 22 farm fields, and subsequent testing didn't find the outbreak pathogen again in the canal. The FDA and CDC's assessments were only a snapshot of a few months, Rock said. The scientists hope with more time, they can shed light on how the water became contaminated to begin with. Produce growers in Arizona and California have since adopted new standards based on the information gleaned from the FDA, including additional water quality testing, increased attention to weather and longer distances from feedlot operations. Claim: UofA scientists to study Yuma lettuce outbreak.

Answer:
University of Arizona scientists are hoping to find more answers about what caused a romaine lettuce outbreak that sickened dozens and put the spotlight on Yuma farmers last year.